The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
p53 regulates a G 2 checkpoint through cyclin B1
Open accessAbstract
The p53 tumor suppressor controls multiple cell cycle checkpoints regulating the mammalian response to DNA damage. To identify the mechanism by which p53 regulates G 2 , we have derived a human ovarian cell that undergoes p53-dependent G 2 arrest at 32°C. We have found that p53 prevents G 2 /M transition by decreasing intracellular levels of cyclin B1 protein and attenuating the activity of the cyclin B1 promoter. Cyclin B1 is the regulatory subunit of the cdc2 kinase and is a protein required for mitotic initiation. The ability of p53 to control mitotic initiation by regulating intracellular cyclin B1 levels suggests that the cyclin B-dependent G 2 checkpoint has a role in preventing neoplastic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Cell Death: The Significance of Apoptosis
Wyllie, A. H., Kerr, J. F. R., & Currie, A. R. (1980) · International Review of Cytology · doi:10.1016/s0074-7696(08)62312-8 · Cited by 7,162
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,336
Caspases: Intracellular Signaling by Proteolysis
Salvesen, G. S., & Dixit, V. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80430-4 · Cited by 2,117
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Cell Cycle Checkpoints: Preventing an Identity Crisis
Elledge, S. J. (1996) · Science · doi:10.1126/science.274.5293.1664 · Cited by 2,039
Cited by
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834
“nor to the oncosuppressive mechanisms that respond to DNA damage by inducing cell death or senescence before mitosis, such as those activated by the G2 checkpoint (see below”
Backgroundp53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
Pucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y., & Hodin, R. A. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.5.1012 · Cited by 544
Biomechanical activation of vascular endothelium as a determinant of its functional phenotype
García-Cardeña, G., Comander, J., Anderson, K. R., Blackman, B. R., & Gimbrone, M. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071052598 · Cited by 523
Fei, P., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206677 · Cited by 498
Cell cycle checkpoint signaling:
Pietenpol, J. A., & Stewart, Z. A. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00460-2 · Cited by 473
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
Personalized characterization of diseases using sample-specific networks
Liu, X., Wang, Y., Ji, H., Aihara, K., & Chen, L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw772 · Cited by 317
Control of the G2/M Transition
Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 279
p21/CDKN1A Mediates Negative Regulation of Transcription by p53
Löhr, K., Möritz, C., Contente, A., & Dobbelstein, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212517200 · Cited by 227
p53 Regulation of G 2 Checkpoint Is Retinoblastoma Protein Dependent
Flatt, P. M., Tang, L. J., Scatena, C. D., Szak, S. T., & Pietenpol, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4210-4223.2000 · Cited by 161
Distinct mechanisms act in concert to mediate cell cycle arrest
Toettcher, J. E., Loewer, A., Ostheimer, G. J., Yaffe, M. B., Tidor, B., & Lahav, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806196106 · Cited by 112
The G2 Checkpoint Is Maintained by Redundant Pathways
Passalaris, T. M., Benanti, J. A., Gewin, L., Kiyono, T., & Galloway, D. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5872 · Cited by 116
“Recent evidence shows cyclin B and CDC2 protein and mRNA down regulation in a p53- and possibly p21-dependent manner (2, 9), and p53’s role may lie in the transcriptional repression of the cyclin B promoter (25).”
Backgroundp130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53
Taylor, W. R., Schönthal, A. H., Galante, J., & Stark, G. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005101200 · Cited by 110
Lossaint, G., Besnard, E., Fisher, D., Piette, J., & Dulić, V (2011) · Oncogene · doi:10.1038/onc.2011.135 · Cited by 83
“On the other hand, p21 was proposed to sustain G2 arrest by inhibiting cyclin B1 and Cdk1 expression (Innocente et al., 1999; Flatt et al., 2000) and by promoting cyclin B1 degradation (Gillis et al.”
B-MYB Is Required for Recovery from the DNA Damage–Induced G2 Checkpoint in p53 Mutant Cells
Mannefeld, M., Klassen, E., & Gaubatz, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4156 · Cited by 82
p53-mediated heterochromatin reorganization regulates its cell fate decisions.
Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., & Aaronson, S. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2271 · Cited by 53
Mohamed-Hussein, Z.-A., & Harun, S. (2009) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-6-18 · Cited by 46
Mechanisms of tolvaptan-induced toxicity in HepG2 cells
Wu, Y., Beland, F. A., Chen, S., Liu, F., Guo, L., & Fang, J.-L. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.015 · Cited by 41
ATP-dependent chromatin remodelers in ageing and age-related disorders
Swer, P. B., & Sharma, R. (2021) · Biogerontology · doi:10.1007/s10522-020-09899-3 · Cited by 25
Metadata
- Authors
- Innocente, S. A., Abrahamson, J. L. A., Cogswell, J. P., & Lee, J. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-02
- Volume
- 96
- Issue
- 5
- Pages
- 2147-2152
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2092409818
- Cited by
- 436
- References
- 46
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.